Publications by authors named "David L Bushnell"

Claim this Profile
C
Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.
Simron Singh, Thomas A Hope, Emily B Bergsland, Lisa Bodei, David L Bushnell

J Natl Cancer Inst· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Charito Love, Neil B Desai, Tony Abraham, Kevin P Banks, Lisa Bodei, David L Bushnell

Am J Clin Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ACR-ACNM-ASTRO-SNMMI Practice Parameter for Lutetium-177 (Lu-177) DOTATATE Therapy.
Charito Love, Neil B Desai, Tony Abraham, Kevin P Banks, Lisa Bodei, David L Bushnell

Clin Nucl Med· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of I-MIBG to PRRT (Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors.
David L Bushnell, Kellie L Bodeker, Thomas M O'Dorisio, Mark T Madsen, Yusuf Menda

J Nucl Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with Lu-DOTATATE.
Jonathan R Strosberg, Rajaventhan Srirajaskanthan, Ghassan El-Haddad, Edward M Wolin, Beth R Chasen, David L Bushnell

J Nucl Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overview and Current Status of Peptide Receptor Radionuclide Therapy.
David L Bushnell, Kellie L Bodeker

Surg Oncol Clin N Am· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with Lu-DOTATATE.
Thomas A Hope, Amanda Abbott, Karen Colucci, David L Bushnell, Linda Gardner

J Nucl Med· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy.
Yusuf Menda, Mark T Madsen, Thomas M O'Dorisio, John J Sunderland, G Leonard Watkins, David L Bushnell

J Nucl Med· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localization of Unknown Primary Site with Ga-DOTATOC PET/CT in Patients with Metastatic Neuroendocrine Tumor.
Yusuf Menda, Thomas M O'Dorisio, James R Howe, Michael Schultz, Joseph S Dillon, David L Bushnell

J Nucl Med· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peptide Receptor Radionuclide Therapy Outcomes in a North American Cohort With Metastatic Well-Differentiated Neuroendocrine Tumors.
Nancy Sharma, Boris G Naraev, Eric G Engelman, M Bridget Zimmerman, David L Bushnell

Pancreas· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.
David L Bushnell, Mark T Madsen, Thomas O'cdorisio, Yusuf Menda, Saima Muzahir

EJNMMI Res· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.
Yusuf Menda, Laura L Boles Ponto, Michael K Schultz, Gideon K D Zamba, G Leonard Watkins, David L Bushnell

Pancreas· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standard imaging techniques for neuroendocrine tumors.
David L Bushnell, Richard P Baum

Endocrinol Metab Clin North Am· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
Matthew H Kulke, Lowell B Anthony, David L Bushnell, Wouter W de Herder, Stanley J Goldsmith

Pancreas· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum.
J Philip Boudreaux, David S Klimstra, Manal M Hassan, Eugene A Woltering, Robert T Jensen, David L Bushnell

Pancreas· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
90Y-edotreotide for metastatic carcinoid refractory to octreotide.
David L Bushnell, Thomas M O'Dorisio, M Sue O'Dorisio, Yusuf Menda, Rodney J Hicks

J Clin Oncol· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modeling combined radiopharmaceutical therapy: a linear optimization framework.
Ian M Besse, Mark T Madsen, David L Bushnell, Malik E Juweid

Technol Cancer Res Treat· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.
Oliver Sartor, Robert H Reid, David L Bushnell, Donald P Quick, Peter J Ell

Cancer· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential increased tumor-dose delivery with combined 131I-MIBG and 90Y-DOTATOC treatment in neuroendocrine tumors: a theoretic model.
Mark T Madsen, David L Bushnell, Malik E Juweid, Yusuf Menda, M Sue O'Dorisio

J Nucl Med· April 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of cardiac to hepatic uptake of 99mTc-tetrofosmin with and without adenosine infusion to predict the presence of haemodynamically significant coronary artery disease.
Shayne R Squires, David L Bushnell, Yusuf Menda, Michael M Graham

Nucl Med Commun· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
9
99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma.
David L Bushnell, Yusuf Menda, Mark T Madsen, Brian K Link, Daniel Kahn

Nucl Med Commun· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer?
Kemp H Kernstine, Kelley A Mclaughlin, Yusuf Menda, Nicholas P Rossi, Daniel J Kahn, David L Bushnell

Ann Thorac Surg· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis